-
1
Blinatumomab in Relapsed/Refractory Burkitt Lymphoma
Published 2022-12-01Subjects: “…Burkitt lymphoma (BL)…”
Get full text
Article -
2
Reduced-Intensity Chemotherapy in Patients With Advanced-Stage Hodgkin Lymphoma
Published 2017-12-01“…The international, randomized phase 3 HD15 trial established 6xeBEACOPP as standard therapy for patients with newly diagnosed advanced-stage Hodgkin lymphoma (HL) within the German Hodgkin Study Group (GHSG). …”
Get full text
Article -
3
CAR T-Cell Persistence Correlates with Improved Outcome in Patients with B-Cell Lymphoma
Published 2023-03-01Subjects: Get full text
Article -
4
Transformed Lymphoma Is Associated with a Favorable Response to CAR-T-Cell Treatment in DLBCL Patients
Published 2021-12-01Subjects: “…diffuse large B-cell lymphoma (DLBCL)…”
Get full text
Article -
5
Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell Lymphoma
Published 2022-09-01Subjects: “…mantle cell lymphoma (MCL)…”
Get full text
Article -
6
Comprehensive Laboratory Diagnostic Workup for Patients with Suspected Intraocular Lymphoma including Flow Cytometry, Molecular Genetics and Cytopathology
Published 2022-01-01Subjects: “…intraocular lymphoma…”
Get full text
Article -
7
Evaluation of Bortezomib-BeEAM (2BeEAM) as Chemotherapy Regimen Prior to ASCT in Patients with Mantle Cell Lymphoma
Published 2023-03-01Subjects: Get full text
Article -
8
OUTCOME OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA RELAPSING AFTER AUTOLOGOUS TRANSPLANT BEFORE AVAILABILITY OF CAR-T CELL TREATMENT
Published 2023-04-01Subjects: “…diffuse large B-cell lymphoma (DLBCL)…”
Get full text
Article -
9
Combining BeEAM with Brentuximab Vedotin for High-Dose Therapy in CD30 Positive Lymphomas before Autologous Transplantation—A Phase I Study
Published 2022-09-01Subjects: Get full text
Article -
10
Correlation of Peripheral Chimeric Antigen Receptor T-cell (CAR-T Cell) mRNA Expression Levels with Toxicities and Outcomes in Patients with Diffuse Large B-cell Lymphoma
Published 2023-08-01Subjects: “…non-hodgkin lymphoma…”
Get full text
Article -
11
-
12
Low-Frequency <i>PPM1D</i> Gene Mutations Affect Treatment Response to CD19-Targeted CAR T-Cell Therapy in Large B-Cell Lymphoma
Published 2023-12-01Subjects: “…Diffuse Large B-cell Lymphoma (DLBCL)…”
Get full text
Article -
13
Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy
Published 2022-05-01Subjects: “…diffuse large B-cell lymphoma (DLBCL)…”
Get full text
Article -
14
Chimeric antigen receptor‐T cell therapy shows similar efficacy and toxicity in patients with diffuse large B‐cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort study
Published 2024-03-01“…Abstract CD19‐directed chimeric antigen receptor (CAR)‐T cell therapy has become a standard treatment for relapsed/refractory diffuse large B‐cell lymphoma (r/r DLBCL). While the benefits of CAR‐T cell treatment are clear in the general patient population, there remains a relative scarcity of real‐world evidence regarding its efficacy and toxicity in patients (pts) aged ≥70 years with DLBCL. …”
Get full text
Article -
15
Humoral Responses to Repetitive Doses of COVID-19 mRNA Vaccines in Patients with CAR-T-Cell Therapy
Published 2022-07-01Subjects: “…diffuse large B-cell lymphoma (DLBCL)…”
Get full text
Article -
16
-
17
HSP90 Inhibitor PU-H71 in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia
Published 2023-08-01Subjects: Get full text
Article -
18
The Evolving Treatment Landscape of AML
Published 2022-03-01“…Over the last years, B-cell lymphoma-2 (BCL-2), a key regulator of the intrinsic apoptotic pathway, has also emerged as a relevant target for therapy for many diseases including AML, and promising results were reported with the use of BCL-2 inhibitors. …”
Get full text
Article -
19
CAR-T Cell Therapy Shows Similar Efficacy and Toxicity in Patients With DLBCL Regardless of CNS Involvement
Published 2023-12-01“…Efficacy and toxicity of chimeric antigen receptor T (CAR-T) cell therapy in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) with central nervous system (CNS) involvement remain understudied. …”
Get full text
Article -
20
Clinical Impact of Single Nucleotide Polymorphism in CD-19 on Treatment Outcome in FMC63-CAR-T Cell Therapy
Published 2023-06-01“…Chimeric antigen receptor (CAR)-T cell therapy is effective in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) with response rates of 63–84% and complete response observed in 43–54%. …”
Get full text
Article